Method and means for treating glomerulonephritis
CA 2317796 A1 · Owner: Pharmalink Baslakemedel Ab · Inventors: Fellstrom, Bengt; Hallgren, Roger
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides the use of a glucocorticoid having a first pass metabolism in the liver of at least 90 % as active substance for the , manufacturing of a medicament for oral or rectal administration in the treatment of glomerulonephritis by releasing the active substance in the intestine. The invention also provides a method for treatment of glomerulonephritis in a native kidney or a kidney transplant with the glucocorticoid as defined above. The invention also comprises a composition comprising the active substance and a pharmaceutically acceptable carrier adjuvant or diluent designed for oral or rectal administration.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 16, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 16, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 16, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.